Figure: J-ALEX-study: superiority of alectinib over crizotinib with regard to PFS (ITT population)
07.07.2016 | SCLC | Online-Artikel
07.07.2016 | SCLC | Online-Artikel
Figure: J-ALEX-study: superiority of alectinib over crizotinib with regard to PFS (ITT population)